Brokerages Set Gilead Sciences, Inc. (NASDAQ:GILD) PT at $91.00

Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) has received a consensus recommendation of “Moderate Buy” from the twenty-two analysts that are currently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $91.00.

GILD has been the topic of a number of research analyst reports. Mizuho boosted their price target on Gilead Sciences from $88.00 to $101.00 and gave the stock a “buy” rating in a research note on Tuesday, February 14th. Morgan Stanley upped their price objective on Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 12th. Robert W. Baird upped their price objective on Gilead Sciences from $69.00 to $80.00 in a research report on Friday, February 3rd. Royal Bank of Canada lowered their price objective on Gilead Sciences from $87.00 to $86.00 and set a “sector perform” rating on the stock in a research report on Monday, March 6th. Finally, Cowen upped their price objective on Gilead Sciences from $90.00 to $95.00 in a research report on Friday, February 10th.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $78.62 on Friday. The company has a market capitalization of $98.07 billion, a PE ratio of 17.75, a P/E/G ratio of 0.91 and a beta of 0.38. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.13 and a current ratio of 1.28. The company has a 50-day simple moving average of $81.10 and a two-hundred day simple moving average of $83.31. Gilead Sciences has a one year low of $57.17 and a one year high of $89.74.

Gilead Sciences (NASDAQ:GILD – Get Rating) last issued its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.26). Gilead Sciences had a return on equity of 39.35% and a net margin of 20.65%. The business had revenue of $6.35 billion for the quarter, compared to analysts’ expectations of $6.33 billion. During the same quarter in the previous year, the firm posted $2.12 EPS. Gilead Sciences’s revenue was down 3.6% on a year-over-year basis. Research analysts expect that Gilead Sciences will post 6.74 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Investors of record on Thursday, June 15th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 3.82%. The ex-dividend date is Wednesday, June 14th. Gilead Sciences’s dividend payout ratio is currently 67.72%.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 6,126 shares of the stock in a transaction on Monday, March 13th. The stock was sold at an average price of $78.99, for a total value of $483,892.74. Following the completion of the transaction, the insider now directly owns 70,130 shares of the company’s stock, valued at approximately $5,539,568.70. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in shares of Gilead Sciences by 1.2% during the 3rd quarter. BlackRock Inc. now owns 128,460,733 shares of the biopharmaceutical company’s stock worth $7,924,739,000 after acquiring an additional 1,523,122 shares during the period. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 112,087,271 shares of the biopharmaceutical company’s stock worth $6,914,663,000 after purchasing an additional 1,691,194 shares during the last quarter. State Street Corp increased its position in shares of Gilead Sciences by 2.2% during the 3rd quarter. State Street Corp now owns 59,240,350 shares of the biopharmaceutical company’s stock worth $3,654,537,000 after purchasing an additional 1,293,414 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 23,848,477 shares of the biopharmaceutical company’s stock worth $2,044,282,000 after purchasing an additional 244,886 shares during the last quarter. Finally, FMR LLC increased its position in shares of Gilead Sciences by 27.2% during the 1st quarter. FMR LLC now owns 20,909,082 shares of the biopharmaceutical company’s stock worth $1,734,826,000 after purchasing an additional 4,470,179 shares during the last quarter. Hedge funds and other institutional investors own 78.72% of the company’s stock.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.